Prevalence of MDS subtypes in Shanghai, China: A comparison of the World Health Organization and French American British classifications

Leukemia Research

Volumn 30, Issue 7, 2006, Pages 769-775

  Irons, Richard D ^a,b   Wang, Xiaoqin ^a,c   Gross, Sherilyn A ^a,b   Bao, Liming ^a,d   Ryder, John ^b   Chen, Yan ^a   Chen, Hui ^a   Sun, Hengjuan ^a   Zhou, Jue ^a   Ji, Meirong ^c   Du, Xinyu ^e   Fu, Hua ^a   Lin, Guowei ^c  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF COLORADO   (United States)

^c FUDAN UNIVERSITY   (China)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cytogenetics; FAB; Myelodysplastic syndrome; RCMD; WHO

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER CLASSIFICATION; CANCER CYTODIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PATIENT; CHINA; CHROMOSOME 20Q; CHROMOSOME 5Q; CHROMOSOME 7Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; TRISOMY 8; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BONE MARROW; CHINA; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PREVALENCE; SENSITIVITY AND SPECIFICITY; WORLD HEALTH ORGANIZATION;

EID: 33744526885     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.10.018     Document Type: Article

References (32)

1. Aul C., Germing U., Gattermann N., and Minning H. Increasing incidence of myelodysplastic syndromes: real or fictitious?. Leuk Res 22 (1998) 93-100
2. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
3. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al., World Health Organization (WHO) International Working Group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96 (2000) 3671-3674
4. Classification of acute leukemia. Ann Intern Med 1977;87:740-53.
5. Jaffe E., Harris N., Stein H., and Vardiman J. In: Kleihues P., and Sobin L.H. (Eds). World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon, France
6. Germing U., Gattermann N., Strupp C., Aivado M., and Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 24 (2000) 983-992
7. Komrokji R.S., and Bennett J.M. The clinical implications of the World Health Organization's classification of myelodysplastic syndromes. Curr Hematol Rep 4 (2005) 175-181
8. Nosslinger T., Reisner R., Koller E., Gruner H., Tuchler H., Nowotny H., et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 98 (2001) 2935-2941
9. Howe R.B., Porwit-MacDonald A., Wanat R., Tehranchi R., and Hellstrom-Lindberg E. The WHO classification of MDS does make a difference. Blood 103 (2004) 3265-3270
10. Chen B., Zhao W.L., Jin J., Xue Y.Q., Cheng X., Chen X.T., et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia 19 (2005) 767-775
11. Lee J.H., Lee J.H., Shin Y.R., Lee J.S., Kim W.K., Chi H.S., et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 17 (2003) 305-313
12. Lee D.S., Kim S.H., Seo E.J., Park C.J., Chi H.S., Ko E.K., et al. Predominance of Trisomy 1q in myelodysplastic syndromes in Korea: is there an ethnic difference? A 3-year multi-center study. Cancer Genet Cytogenet 132 (2002) 97-101
13. Oguma S., Yoshida Y., Uchino H., Maekawa T., Nomura T., and Mizoguchi H. Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Anemia Study Group of the Ministry of Health and Welfare. Leuk Res 19 (1995) 219-225
14. Intragumtornchai T., Prayoonwiwat W., Swasdikul D., Suwanwela N., Chaimongkol B., Jootar S., et al. Myelodysplastic syndromes in Thailand: a retrospective pathologic and clinical analysis of 117 cases. Leuk Res 22 (1998) 453-460
15. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
16. Heim S., and Mitelman F. Cancer cytogenetics (1995), Wiley-Liss, New York
17. Matsushima T., Handa H., Yokohama A., Nagasaki J., Koiso H., Kin Y., et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood 101 (2003) 3386-3390
18. Balduini C.L., Guarnone R., Pecci A., Centenara E., Invernizzi R., and Ascari E. The myelodysplastic syndromes: predictive value of eight prognostic systems in 143 cases from a single institution. Haematologica 84 (1999) 12-16
19. Parlier V., van Melle G., Beris P., Schmidt P.M., Tobler A., Haller E., et al. Prediction of 18-month survival in patients with primary myelodysplastic syndrome. A regression model and scoring system based on the combination of chromosome findings and the Bournemouth score. Cancer Genet Cytogenet 81 (1995) 158-165
20. Sole F., Espinet B., Sanz G.F., Cervera J., Calasanz M.J., Luno E., et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol De Citogenetica Hematologica. Br J Haematol 108 (2000) 346-356
21. Vallespi T., Imbert M., Mecucci C., Preudhomme C., and Fenaux P. Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica 83 (1998) 258-275
22. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3849
23. Standing Committee on Human Cytogenetic Nomenclature. An international system for human cytogenetic nomenclature (1995): recommendations of the international standing committee on human cytogenetic nomenclature, Memphis, Tenn., October 1994. New York: Karger; 1995.
24. Toyama K., Ohyashiki K., Yoshida Y., Abe T., Asano S., Hirai H., et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 7 (1993) 499-508
25. Matsuda A., Germing U., Jinnai I., Misumi M., Kuendgen A., Knipp S., et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 106 (2005) 2633-2640
26. Mandel K., Dror Y., Poon A., Freedman M.H., and Practical A. Comprehensive classification for pediatric myelodysplastic syndromes: the CCC system. J Pediatr Hematol Oncol 24 (2002) 343-352
27. Shu X.O., Gao Y.T., Brinton L.A., Linet M.S., Tu J.T., Zheng W., et al. A population-based case-control study of childhood leukemia in Shanghai. Cancer 62 (1988) 635-644
28. Irons RD, Lv L, Gross SA, Ye X, Bao L, Wang XQ, et al., Chronic exposure to benzene results in a unique form of dysplasia. Leuk Res, 2005;29:1371-80.
29. Barrett A.J. Myelodysplastic syndrome-an example of misguided immune surveillance?. Leuk Res 28 (2004) 1123-1124
30. Rosenfeld C., and List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia 14 (2000) 2-8
31. Biesma D.H., van den Tweel J.G., and Verdonck L.F. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 79 (1997) 1548-1551
32. Matsutani T., Yoshioka T., Tsuruta Y., Shimamoto T., Ohyashiki J.H., Suzuki R., et al. Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia. Leuk Res 27 (2003) 305-312